Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 6/20 | 0.40 |
| ▸ | REN | P00797 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272125 | 0.77 | MC3R (0.38) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL29182008 | 0.77 | HSD17B10 (0.40) | LMNAHSD17B10CYP2C19PREPACE | |
| SCHEMBL13980014 | 0.77 | CYP2C19 (0.37) | LMNAHSD17B10CYP2C19PREPACE | |
| SCHEMBL3847396 | 0.77 | ACE (0.41) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL25305712 | 0.77 | ACE (0.41) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL338313 | 0.77 | HSD17B10 (0.46) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL28737989 | 0.77 | DPP4 (0.43) | LMNAHSD17B10CYP2C19PREPACE | |
| SCHEMBL15229046 | 0.77 | ACE (0.41) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL18444823 | 0.77 | ACE (0.41) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL2236647 | 0.77 | ACE (0.41) | LMNAHSD17B10CYP2C19ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | LMNA 3500/4885HSD17B10 4096/4885CYP2C19 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.